Atherosclerotic Cardiovascular Disease
At KardioLEV s.r.o. researchers are focusing on atherosclerotic cardiovascular disease, testing a novel lipid‑lowering agent to lower the risk of major adverse cardiovascular events (MACE) such as heart attack and stroke.
- Atherosclerotic plaque buildup
- Lipid‑modifying therapy evaluation
- Cardiovascular event reduction
The site in Levoca, Slovakia is conducting four trials with four investigators, all within the cardiovascular therapeutic area.
Atrial Fibrillation and Stroke Prevention
The centre is conducting studies in atrial fibrillation to improve prevention of stroke and systemic embolism, comparing the new anticoagulant asundexian with standard therapy.
- Stroke prevention
- Bleeding risk comparison
- Anticoagulant efficacy
Based in Levoca, Slovakia, KardioLEV s.r.o. is running four cardiovascular trials with a dedicated team of four investigators.
Heart Failure with Preserved/Mildly Reduced Ejection Fraction & Obesity
In patients with heart failure with preserved or mildly reduced ejection fraction and obesity, trials evaluate the drug maridebart cafraglutide to reduce hospitalizations and cardiovascular death.
- Heart failure events
- Weight‑related outcomes
- Cardiovascular mortality
KardioLEV s.r.o., located in Levoca, Slovakia, contributes four clinical studies led by four investigators, all centered on cardiovascular health.
